Cost–effectiveness of carbamazepine in epilepsy

References

• NICE. The diagnosis and care of children and adults with epilepsy. London, NICE, Report No.: CG20 (2004).
   Google Scholar
• Heaney D, Shorvon S, Sander JW et al. A cost minimisation study comparing the use of anti-epileptic drugs in newly diagnosed epilepsy in 11 European countries. Epilepsia 41(Suppl. 5), S37–S44 (2000).
   PubMedGoogle Scholar
• Heaney DC, Shorvon SD, Sander JW. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 39 (Suppl. 3), S19–S25 (1998).
   PubMed Web of Science ®Google Scholar
• Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure 7(2), 119–125 (1998).
   PubMed Web of Science ®Google Scholar
• Bryant J, Stein K. Lamotrigine as monotherapy in the treatment of partial epilepsy. Wessex Institute for Health Research and Development (1998).
   Google Scholar
• Remak E, Hutton J, Price M, Peeters K, Adriaenssen I. A Markov model of treatment of newly diagnosed epilepsy in the UK. An initial assessment of cost–effectiveness of topiramate. Eur. J. Health. Econ. 4(4), 271–278 (2003).
   PubMedGoogle Scholar
• Hawkins N, Epstein D, Drummond M et al. Assessing the cost–effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Med. Decis. Making 25(5), 493–510 (2005).
   PubMed Web of Science ®Google Scholar
• Schachter SC, Sommerville KW, Ryan JE. A cost–effectiveness analysis of tiagabine, phenytoin, and carbamazepine adjunctive therapy for patients with complex partial seizures. Neurology 52(Suppl. 6), A143 (1999).
   Google Scholar
• Young JD. FDA policy on generic anticonvulsants. Scrip 1469, 28 (1989).
   Google Scholar
• British Pharmacopeia Commission. British Pharmacopaeia. The Stationary Office (2005).
   Google Scholar
• Commission of the European Communities. Directive 91/356/EEC. Off. J. Eur. Communities 142(11) (1991).
   Google Scholar
• Mahmood I, Chamberlin N, Tammara V. A limited sampling approach in bioequivalence studies. Ther. Drug Monit. 19, 413–419 (1997).
   Google Scholar
• Bialer M, Arcavi L, Sussan S et al. Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine. Epilepsy Res. 32, 371–378 (1998).
   Google Scholar
• Bialer M, Yacobi A, Moros D, Levitt B, Houle JM, Munsaka MS. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia 39(5), 513–519 (1998).
   Google Scholar
• Crawford P, Hall WW, Chappell B, Collings JA, Steward A. Generic prescribing for epilepsy: is it safe? Seizure 5, 1–5 (1996).
   Web of Science ®Google Scholar
• Beach R, Reading R. Generic prescribing for epilepsy. Is it safe? Seizure 6, 327 (1997).
   Google Scholar
• Argumosa A, Herranz JL. The clinical and economic impact of generic drugs in the treatment of epilepsy. Rev. Neurol. 41(1), 45–49 (2005).
   PubMed Web of Science ®Google Scholar
• Spitz MC. Injuries and death as a consequence of seizures in people with epilepsy. Epilepsia 39(8), 904–907 (1998).
   PubMedGoogle Scholar
• Garnett WR, Gilbert TD, O’Connor P. Patterns of care, outcomes, and direct health plan costs of anti-epileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations. Clin. Ther. 27(7), 1092–1103 (2005).
   Google Scholar
• Audit Commission. A prescription for improvement: towards more rational prescribing in general practice. London: HMSO (1999).
   Google Scholar
• Cohen LJ, Shelton RC, Brown B et al. The use of generic mood stabilizers. J. Clin. Psych.15(4), 1–38 (1997).
   Google Scholar
• French JA. The long-term therapeutic management of epilepsy. Ann. Intern. Med. 120, 411–422 (1994).
   PubMedGoogle Scholar
• McGill I. Prescribing anticonvulsants. The Pharmaceutical Journal 261, 793 (1998).
   Google Scholar
• Neuhauser M, Frazier J. Should generic carbamazepine be substituted for Tegretol? Premier Purchasing partners, 1–5 (1996).
   Google Scholar
• Nuwer MR, Browne TR, Dodson WE et al. Generic substitutions for anti-epileptic drugs. Neurology 40, 1647–1651 (1990).
   PubMed Web of Science ®Google Scholar
• Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: generic substitution for anti-epileptic medication. Neurology 40, 1641–1643 (1990).
   PubMed Web of Science ®Google Scholar
• Besag FM. Is generic prescribing acceptable in epilepsy? Drug Saf. 23(3), 173–182 (2000).
   PubMed Web of Science ®Google Scholar
• Jobst BC, Holmes GL. Prescribing anti-epileptic drugs: should patients be switched on the basis of cost? CNS Drugs 18(10), 617–628 (2004).
   Google Scholar
• Petersen KU. Original brands and generic preparations. Med. Klin. (Munich) 95(1), 26–30 (2000).
   Google Scholar
• Oles KS, Penry JK, Smith LD, Anderson RL, Dean JC, Riela AR. Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 42, 1147–1153 (1992).
   Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of anti-epileptic drugs. Epilepsia 45(11), 1330–1337 (2004).
   PubMed Web of Science ®Google Scholar
• Miller AD, Krauss GL, Hamzeh FM. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol. Scand. 109(6), 374–377 (2004).
   PubMed Web of Science ®Google Scholar
• Ficker DM, Privitera M, Krauss G, Kanner A, Moore JL, Glauser T. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology 65(4), 593–595 (2005).
   PubMed Web of Science ®Google Scholar
• Heaney DC, Sander JW, Shorvon SD. Comparing the cost of epilepsy across eight European countries. Epilepsy Res. 43(2), 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Overstall PW, Giorgi L. Multi-centre, double-blind, randomised comparision between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res. 37, 81–87 (1999).
   PubMed Web of Science ®Google Scholar
• Morrow JI, Russell A, Gutherie E et al. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry 12, jnnp (2005).
   Google Scholar
  Chisholm D, WHO. Cost–effectiveness of first-line anti-epileptic drug treatments in the developing world: a population-level analysis. Epilepsia 46(5), 751–759 (2005).
   Google Scholar
• Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 45(9), 1141–1149 (2004).
   PubMed Web of Science ®Google Scholar